These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29616539)

  • 1. [Controlled-release oxycodone in the treatment of chronic musculoskeletal pain: A preliminary experience of rheumatology center].
    Grazio S; Grubišić F; Knež V; Kavanagh HS; Nemčić T
    Reumatizam; 2016; 63(1):20-3. PubMed ID: 29616539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain.
    Coluzzi F; Ruggeri M
    Curr Med Res Opin; 2014 Jun; 30(6):1139-51. PubMed ID: 24528146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
    Hale M; Tudor IC; Khanna S; Thipphawong J
    Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged-release oxycodone/naloxone in nonmalignant pain: single-center study in patients with constipation.
    Gatti A; Casali M; Lazzari M; Tufaro G; Gafforio P; Silvestri C; Marcassa C; Sabato AF
    Adv Ther; 2013 Jan; 30(1):41-59. PubMed ID: 23269562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching to low-dose oral prolonged-release oxycodone/naloxone from WHO-Step I drugs in elderly patients with chronic pain at high risk of early opioid discontinuation.
    Lazzari M; Marcassa C; Natoli S; Carpenedo R; Caldarulo C; Silvi MB; Dauri M
    Clin Interv Aging; 2016; 11():641-9. PubMed ID: 27257377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of oxycodone controlled-release immediately after NSAIDs: a new approach to obtain good pain control.
    Tessaro L; Bandieri E; Costa G; Fornasier G; Iorno V; Pizza C; Pastacaldi G; Micheletto G
    Eur Rev Med Pharmacol Sci; 2010 Feb; 14(2):113-21. PubMed ID: 20329570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled-release oxycodone tablets after transdermal-based opioid therapy in patients with cancer and non-cancer pain.
    Ravera E; Di Santo S; Bosco R; Arboscello C; Chiarlone R
    Aging Clin Exp Res; 2011; 23(5-6):328-32. PubMed ID: 22526067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain.
    Yoon DH; Bin SI; Chan SK; Chung CK; In Y; Kim H; Lichauco JJ; Mok CC; Moon YW; Ng TK; Penserga EG; Shin DA; You D; Moon H
    BMC Musculoskelet Disord; 2017 Aug; 18(1):337. PubMed ID: 28778219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic study on the impact of side effects in patients taking oxycodone controlled-release for noncancer pain.
    Anastassopoulos KP; Chow W; Tapia CI; Baik R; Ackerman SJ; Biondi D; Kim MS
    J Manag Care Pharm; 2012 Oct; 18(8):615-26. PubMed ID: 23127149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of High-Dose Controlled-Release Oxycodone in the Treatment of Moderate to Severe Pain in Patients with Advanced Cancer: A Retrospective Study.
    Wang W; Song Z; Zhang Y
    Med Sci Monit; 2018 Sep; 24():6750-6755. PubMed ID: 30229751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study.
    Portenoy RK; Farrar JT; Backonja MM; Cleeland CS; Yang K; Friedman M; Colucci SV; Richards P
    Clin J Pain; 2007 May; 23(4):287-99. PubMed ID: 17449988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studies.
    Merchant S; Provenzano D; Mody S; Ho KF; Etropolski M
    J Opioid Manag; 2013; 9(1):51-61. PubMed ID: 23709304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of the first oxycodone once daily prolonged release tablet in moderate to severe chronic pain: a randomized, double-blind, multicenter, cross-over, non-inferiority study to investigate efficacy and safety in comparison with an established oxycodone twice daily prolonged release tablet.
    Lux EA; Janecki M; Maritz MA
    Curr Med Res Opin; 2014 Nov; 30(11):2365-75. PubMed ID: 25050592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study.
    Hale ME; Dvergsten C; Gimbel J
    J Pain; 2005 Jan; 6(1):21-8. PubMed ID: 15629415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of oxycodone-naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study.
    Guerriero F; Roberto A; Greco MT; Sgarlata C; Rollone M; Corli O
    Drug Des Devel Ther; 2016; 10():1515-23. PubMed ID: 27143857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged release oxycodone and naloxone treatment counteracts opioid-induced constipation in patients with severe pain compared to previous analgesic treatment.
    Koopmans-Klein G; Van Op den Bosch J; van Megen Y; Prenen H; Huygen F; Mancini I
    Curr Med Res Opin; 2017 Dec; 33(12):2217-2227. PubMed ID: 28805471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain.
    Arora S; Setnik B; Michael D; Hudson JD; Clemmer R; Meisner P; Pixton GC; Goli V; Sommerville KW
    J Opioid Manag; 2014; 10(6):423-36. PubMed ID: 25531960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study.
    Gatti A; Sabato AF; Carucci A; Bertini L; Mammucari M; Occhioni R
    Clin Drug Investig; 2009; 29 Suppl 1():31-40. PubMed ID: 19445553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain.
    Richarz U; Waechter S; Sabatowski R; Szczepanski L; Binsfeld H
    Pain Pract; 2013 Jan; 13(1):30-40. PubMed ID: 22510252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-naive cancer pain patients, starting with 5 mg tablets.
    Koizumi W; Toma H; Watanabe K; Katayama K; Kawahara M; Matsui K; Takiuchi H; Yoshino K; Araki N; Kodama K; Kimura H; Kono I; Hasegawa H; Hatanaka K; Hiraga K; Takeda F
    Jpn J Clin Oncol; 2004 Oct; 34(10):608-14. PubMed ID: 15591459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.